ClinicalTrials.gg

Program

Carbon-14

Also written as “Carbon-14 BIA 28-6156”, “Carbon-14 labeled HSK39297” and “carbon-14-[14C]-ANG-3777”.

Its studies are mostly in Parkinson Disease · Hemoglobinuria, Paroxysmal · Diabetes Mellitus, Type 2, led by 4 companies.

Furthest: phase 1, since May 28, 20214 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Angion Biomedica10 open or runningphase 1since May 28, 2021May 28, 2021none ahead
Bial - Portela C10 open or runningphase 1since Nov 18, 2021Nov 18, 2021none ahead
GlaxoSmithKline10 open or runningphase 1since Jul 9, 2009Jul 9, 2009none ahead
Haisco Pharmaceutical Group10 open or runningphase 1since Feb 24, 2025Feb 24, 2025none ahead

Also a collaborator on its studies: quotient-sciences.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 9, 2009First study: phase 1 study in Diabetes Mellitus, Type 2New to GlaxoSmithKlineGlaxoSmithKline · NCT00937872 · 9 enrolled · United Kingdom
  2. May 28, 2021Angion Biomedica's first study: phase 1 study in HealthyNew to Angion BiomedicaAngion Biomedica · NCT04931524 · 6 enrolled · United Kingdom
  3. Nov 18, 2021Bial - Portela C's first study: phase 1 study in Parkinson DiseaseNew to Bial - Portela CBial - Portela C · NCT05220072 · 6 enrolled · United Kingdom
  4. Feb 24, 2025Haisco Pharmaceutical Group's first study: phase 1 study in Hemoglobinuria, ParoxysmalNew to Haisco Pharmaceutical GroupHaisco Pharmaceutical Group · NCT06852092 · 7 enrolled · China

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06852092Hemoglobinuria, Paroxysmal · China1CompletedHaisco Pharmaceutical GroupSep 27, 20247
NCT05220072Parkinson Disease · United Kingdom1CompletedBial - Portela COct 16, 20216
NCT04931524Healthy · United Kingdom1UNKNOWNAngion BiomedicaJun 20216
NCT00937872Diabetes Mellitus, Type 2 · United Kingdom1CompletedGlaxoSmithKlineDec 22, 20089

How it is read

Names in the registry

  • “Carbon-14 BIA 28-6156”, 1 entry
  • “Carbon-14 labeled HSK39297”, 1 entry
  • “carbon-14-[14C]-ANG-3777”, 1 entry
  • “Carbon-14 radio-labeled SRT2104”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.